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Incidents in Molecular Pathology
Frequency and Causes During Routine Testing
Cleo Keppens, PhD; Yann Van Royen, MS; Anne Brysse, PhD; Sophie Cotteret, PhD; Estrid Høgdall, MD, PhD;
Tine Plato Kuhlmann, MD, PhD; Brendan O’Sullivan, PhD; Patrick Pauwels, MD, PhD; Siegrid Pauwels, PhD; Mitja Rot, PhD;
Nancy Vanderheyden, MS; Ilse Van Hee, MS; Elisabeth MC Dequeker, PhD
 Context.—Errors in laboratory medicine could compro-
mise patient safety. Good laboratory practice includes
identifying and managing nonconformities in the total test
process. Varying error percentages have been described in
other fields but are lacking for molecular oncology.
Objectives.—To gain insight into incident causes and
frequency in the total test process from 8 European
institutes routinely performing biomarker tests in non-
small cell lung cancer and colorectal cancer.
Design.—All incidents documented in 2018 were
collected from all hospital services for pre-preanalytical
entries before the biomarker test, as well as specific
incidents for biomarker tests.
Results.—There were 5185 incidents collected, of which
4363 (84.1%) occurred in the pre-preanalytical phase (all
hospital services), 2796 of 4363 (64.1%) related to missing
or incorrect request form information. From the other 822
specific incidents, 166 (20.2%) were recorded in the
preanalytical phase, 275 (33.5%) in the analytical phase,
and 194 (23.6%) in the postanalytical phase, mainly due to
incorrect report content. Only 47 of 822 (5.7%) incidents
were recorded in the post-postanalytical phase, and 123
(15.0%) in the complete total test process. For 17 of 822
(2.1%) incidents the time point was unknown. Pre-
preanalytical incidents were resolved sooner than inci-
dents on the complete process (mean 6 versus 60 days). For
1215 of 5168 (23.5%) incidents with known causes a
specific action was undertaken besides documenting them,
not limited to accredited institutes.
Conclusions.—There was a large variety in the number
and extent of documented incidents. Correct and complete
information on the request forms and final reports are
highly error prone and require additional focus.
(Arch Pathol Lab Med. doi: 10.5858/arpa.2020-0152-
OA)
Errors in laboratory medicine could significantly com-promise patient safety. According to the International
Organization for Standardization (ISO) technical specifi-
cation ISO/TS 22367:2008, all clinical laboratories must (1)
implement measures to detect high-risk processes, (2)
identify incidents and associated risks to patient safety,
and (3) monitor the effectiveness of corrective actions.1
Over the last decade, various studies have focused on
estimating the percentage of different error types in
several fields of laboratory medicine. The frequency of
identified laboratory errors varies greatly, depending on
the study design, country, laboratory procedures, and
investigated steps of the total testing process (TTP). This
TTP includes the preanalytical, analytical, and postanalyt-
ical phases, first referred to as the brain-to-brain loop by
Lundberg et al.2
A ranging error percentage has been described in clinical
biochemistry, hematology, and immunology of 0.1% up to
36.8%, with a variable distribution of 45.5% to 89.6% errors in
the preanalytical phase, 2.6% to 18.0% in the (intra-)analytical
phase, and 7.7% to 47.0% in the postanalytical phase.3–8 In
forensic genetics, the postanalytical phase was reported to be
the major source of erroneous results with 61.9% postanalyt-
ical problems of the total error rate of 0.5%.9
Over time, a reduction in the analytical error rate was
reported due to improvements in the reliability and
standardization of analytical techniques, reagents, and
instrumentation, but also advances in information tech-
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nology, quality control, and quality assurance methods.10
Focus thus shifted toward the initial and final steps of the
TTP outside the laboratories’ test scope as possible
compromising factors of the total test integrity.11 These
steps are often referred to as the pre-preanalytical phase
and post-postanalytical phase, with estimated error rates
contributing to 12% and 5% of the total errors, respec-
tively.12
Of the (pre-) preanalytical errors, incomplete request form
completion has been one of the most frequently reported
incidents.4,5,13 Several elements were lacking or incorrect,
such as the clinical information on previous medication,14
contact details of the requesting physician,15,16 or a
mismatch of the received sample with the patient identifi-
cation.17
On the other hand, nonadherence to predefined sample
acceptance criteria was also frequently reported,4,5,13 espe-
cially for blood sample collection. In the post-postanalytical
phase, reported incidents included (1) an inappropriate
response to the receipt, interpretation, and utilization of
laboratory information by the clinician, (2) feedback from
clinicians, or (3) feedback on test results by providers of
external quality assessment (EQA) programs. Examples are
an excessive turnaround time and unreported critical values
in the final report.5
Despite these studies, no information is available yet on
the distribution of incidents in the TTP from laboratories
testing predictive biomarkers in molecular oncology. As
these tests convey necessary information for the selection of
an appropriate targeted therapy, errors could result in a
denial or unnecessary delivery of these therapies to cancer
patients. Medical laboratories performing these tests are
recommended to apply for ISO 15189:2012 accreditation.18
This standard specifies that laboratories should (1) imple-
ment a documented procedure to identify and manage
nonconformities in any aspect of the quality management
system and for all TTP phases, (2) determine the root causes
of these nonconformities, (3) take action to eliminate the
cause(s), and (4) perform a risk analysis on the impact on
patient safety.18
A recent study on the management of EQA results in
metastatic colorectal cancer (mCRC) and non-small cell
lung cancer (NSCLC) revealed that incorrect outcomes
occurred throughout the different test phases. More
specifically, of the 514 cases, 92 (17.9%) occurred in the
preanalytical phase, 166 (32.3%) in the analytical phase, 226
(44.0%) in the postanalytical phase, and for 30 (5.8%) cases
the exact time point was unknown.29 Also, underlying error
causes varied largely on the tested biomarker and applied
analysis techniques. For these problems, many laboratories
reported that they did not initiate any corrective or
preventive actions (CAPAs), an observation that also
occurred in accredited institutes.29 As EQA programs send
precut and prelabeled samples, several pre-preanalytical
processes cannot be studied, such as the test request, sample
reception and data entry, and sample preparation.
This study aimed to provide an overview of root causes
and distribution throughout the TTP of documented
incidents in 2018 by 8 clinical institutes routinely performing
biomarker tests in NSCLC and mCRC.
MATERIALS AND METHODS
Eight institutes were included in this cross-sectional study,
comprising 4 Belgian laboratories and 4 other European laborato-
ries for comparison (Denmark, France, Slovenia, and the United
Kingdom). The institutes were selected based on (1) our contacts in
a larger project of biomedical sciences student internships, (2) on
the delivery of routine biomarker testing for targeted therapy
selection in NSCLC and mCRC, (3) on the possibility of providing
an export of the documented incidents, and (4) on the institutes’
availability during the study period. Institutes that did not perform
molecular oncology tests for NSCLC and mCRC or did not keep
any incident records were excluded. As ISO 15189:201218 accred-
itation is obligatory in Belgium for reimbursement of the performed
analyses, all Belgian laboratories were accredited, compared with 2
of 4 European institutes. An overview of the institutes’ character-
istics (country, accreditation, setting, number of samples tested,
number of people involved, average turnaround time, etc), and
collected data (software for incident reporting, number of incidents
documented, and type of information provided) is shown in Table
1.
From these institutes, all incidents that were routinely docu-
mented in a time period between January 1, 2018 and December
31, 2018 were collected and analyzed. Incidents in this manuscript
are defined as follows: ‘‘all non-conformities, adverse events, or
deviations from the standard operating procedure, occurring
throughout all test phases, and identified in any way (including
clinician complaints, internal quality control indications, instru-
ment calibrations, checking of consumable materials, interlabor-
atory comparisons, staff comments, reporting and certificate
checking, laboratory management, reviews, and internal and
external audits).’’
Incidents related to the pre-preanalytical phase (from the clinical
question up to the test request, sample reception and entry) were
collected at all hospital services because many of the laboratory
information systems (LIS) do not discriminate between incidents at
different services at this stage (the database for incident collection
can be integrated into or separate from the laboratory information
system, therefore when referring to the term LIS in this manuscript
we refer to the database used for incident registration). From there
on in the TTP (ie, from the preanalytical to the post-postanalytical
phase), collected incidents were specific for performed biomarker
tests in NSCLC and mCRC. The collected data were anonymized
for patient information, and an additional nondisclosure agreement
was signed with the institutes to safeguard the confidentiality of
any medical or personal data that were still visible. These data were
checked for completeness by the institutes and once more before
analysis. All collected data were combined and blinded for the
institute. Names of staff members who reported the incidents were
replaced by their appropriate function in the laboratory for an
objective comparison. Documented incidents were further catego-
rized depending on the time point of occurrence (phase in the
TTP), their causes, and actions undertaken. Frequencies and cross
tabulations were used to summarize descriptive statistics. For this
type of work, no institutional review board approval was needed at
our institution.
RESULTS
In total, 5185 incidents were collected, of which 4363
(84.1%) occurred in the pre-preanalytical phase comprising
all hospital services. For the other 822 collected incidents,
which were specific for biomarker testing in NSCLC and
mCRC, 166 (20.2%) were recorded in the preanalytical
phase, 275 (33.5%) in the analytical phase, 194 (23.6%) in
the postanalytical phase, and 47 (5.7%) in the post-
postanalytical phase. Another 123 of 822 incidents (15.0%)
concerned the complete TTP (infrastructure or documenta-
tion, etc) and for 17 (2.1%) incidents the exact time point in
the TTP was unknown.
The exact phase and time point of occurrence for the
collected incidents is shown in Figure 1, except for 17
incidents for which the time point was unknown. During
the pre-preanalytical phase, 2796 of 4363 (64.1%) incidents
were reported during the test request (ie, filling of the
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request form), and 1008 of 4363 (23.1%) incidents during
sample reception. Looking at the causes of the pre-
preanalytical incidents, 2796 of 4363 (64.1%) were due to
missing or incorrect information on the request form sent by
the treating physician (Table 2). In more detail, (1) for 737 of
2796 (26.4%) incidents the clinical information (ie, previous
patient history or acceptance criteria to perform the correct
test) was lacking or incorrect, (2) the information for test
reimbursement by the health insurance was missing in 557
of 2796 (19.9%) forms, or (3) the date of sample collection
was absent in 552 of 2796 (18.7%) requests. For 1054 of 4363
(24.2%) incidents, the received sample material did not meet
the laboratory’s predefined acceptance criteria. This entailed
an insufficient specimen amount or volume in 355 of 1054
(33.7%) cases, incorrect sample collection for 301 of 1054
(28.6%) incidents, or an absent/incorrect patient identifier
for 222 of 1054 (21.1%) cases. For 352 of 4363 (8.1%)
incidents, the material that was received did not match the
description on the request form, in 251 of 352 cases (71.3%)
because the form mentioned more or fewer specimens
compared to the number of available samples.
The remaining 161 of 4363 (3.7%) pre-preanalytical
incidents occurred when the material and request form
were acceptable but were incorrectly entered in the LIS.
Looking at the biomarker-specific incidents in the other
phases, incidents occurred most often during specimen
sectioning (58 of 166 preanalytical incidents [34.9%]), the
analysis itself (214 of 275 analytical incidents [77.8%]),
drafting of the report (157 of 194 postanalytical incidents
[80.9%]), and feedback on the results by the treating
physician or EQA provider (30 of 47 post-postanalytical
incidents [63.8%]) (Figure 1). Another 15 of 4363 (0.4%), 8
of 166 (4.8%), and 2 of 275 (0.7%) incidents occurred when
forwarding the case for further processing to the next phase
(Figure 1).
The underlying causes of NSCLC and mCRC specific
incidents are presented in Table 3. The most frequent causes
were sample switches in 35 of 166 (21.1%) preanalytical
incidents, failed immunohistochemistry or fluorescence in
situ hybridization tests in 42 of 275 (15.3%) analytical
incidents, errors in the final report content of 152 of 194
(78.4%) postanalytical incidents, and documentation of
EQA program results in 26 of 47 (55.3%) incidents of the
post-postanalytical phase. For the 152 incidents on the
report content, 44 (28.9%) reports had an incorrect test
result or conclusion, 27 (17.8%) had an incorrect patient
name or date of birth, and for 18 (11.8%) reports the time of
validation occurred too soon or too late in the TTP. For the
123 incidents that affected the complete TTP, the necessary
documentation or procedures were not kept in 39 (31.7%)
issues, equipment maintenance was delayed in 20 (16.3%)
incidents, and delayed document review was the basis for
error in 13 (10.6%) incidents.
The incident causes were classified according to the
relevant clauses of the ISO 15189:2012 standard and are
depicted in Figure 2. Incidents with an unknown cause were
excluded (17 of 5185) as well as pre-preanalytical incidents
(4363 of 5185), as they were all related to clause 5.4, pre-
examination processes. For the remaining 805 of 5185
entries, 107 of 805 (13.3%) were related to the standard’s
management requirements. In more detail, 42 of 805 (5.2%)
were related to clause 4.3, document control, and 32 (4.0%)
to clause 4.14, evaluation and audits.
The other 698 of 805 (86.7%) incidents were related to the
technical requirements, in 198 of 805 (24.6%) cases for
clause 5.3, laboratory equipment, reagents, and consum-
ables, in 129 of 805 (16.0%) cases for clause 5.6, ensuring the
quality, and in 126 of 805 (15.7%) cases for clause 5.8,
reporting of examination results.
Figure 1. Time point of incident occurrence
in the total test process. Percentages represent
the percentage of incidents being document-
ed within their respective phase. Pre-preana-
lytical incidents were collected for all hospital
services. Other incidents were specific for
predictive biomarker testing in NSCLC and
mCRC. Abbreviations: EQA, external quality
assessment; H&E, hematoxylin and eosin;
mCRC, metastatic colorectal cancer; NSCLC,
non-small cell lung cancer.
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There was a wide variety in the number of documented
incidents and recorded data per incident between the 8
institutes (Supplemental Table 1, see supplemental digital
content containing 3 tables and 1 figure). One laboratory did
not document pre-preanalytical incidents, while the other 7
institutes documented 7 to 2748 pre-preanalytical incidents
in 2018. At 4 institutes, mainly analytical incidents were
documented, with percentages ranging from 51 of 163
(31.3%) to 37 of 51 (72.5%). For 3 other institutes, the bulk
of incidents occurred in the preanalytical, postanalytical, or
complete TTP, respectively.
All institutes recorded the date of incident notification, the
root case, and classified the incidents depending on the
cause. Six laboratories mentioned the action plan, and 5 of
them also evaluated the effectiveness of that plan. Other
recorded elements were only documented by 2 institutes,
such as the designated staff member for follow-up, the
means of incident discovery, and how awareness was raised
among the staff (Supplemental Table 1).
When comparing all incidents (with the exception of 17 of
5185 incidents with an unknown cause), for 3953 of 5168
(76.5%) incidents no immediate action was explicitly
documented besides recording of the incident in the LIS
for quality monitoring (Supplemental Table 2). In case a
specific action was reported, the most frequent actions
included contacting the requesting physician for 564 of 4363
(12.9%) pre-preanalytical incidents. Samples were retested
for 27 of 166 (16.3%) preanalytical incidents, and for 62 of
275 (22.5%) analytical incidents. In the postanalytical phase
report validation and correction were most often reported,
for 83 of 194 (42.8%) cases.
In the post-postanalytical phase, 6 of 47 (12.8%) incidents
were communicated to the staff for improvement and an
Table 2. Causes of Pre-Preanalytical Incidents
Documented Across All Hospital Services
Causes of Pre-Preanalytical
Incidents (N ¼ 4363) n %
Information on the request form 2796 64.1
Clinical information absent or incorrect 737 26.4
Clinical info absent or incorrect (further
unspecified)
466 63.2
Clinical acceptance criteria to perform the
test missing
120 16.3
Clinical info form not attached to request
form
92 12.5
Missing information about genetic
counseling
28 3.8
Previous testing info necessary to perform
the test lacking
28 3.8
Clinical info present, but unreadable 3 0.4
Information for reimbursement lacking 557 19.9
No date of collection present 522 18.7
No, incomplete or incorrect information
about requesting physician or hospital
290 10.4
Sample type lacking or incorrect 261 9.3
No or incorrect test requested 149 5.3
No date of request present 105 3.8
Inconsistent or missing information (further
unspecified)
94 3.4
Incorrect or absent patient name (first or
surname or both)
35 1.3
Informed consent absent 24 0.9
Incorrect or absent date of birth 9 0.3
Incorrect sample localization mentioned 7 0.3
Incorrect/outdated request form template used 6 0.2
Sample acceptance criteria 1054 24.2
Insufficient sample material/volume received 355 33.7
Problem with sample collection 301 28.6
Heparin/EDTA/coagulant/citrate missing 161 53.5
Contamination of amniotic sample by
maternal cells
66 21.9
Expired paper for blood spots used 53 17.6
Plasma not separated from debris 10 3.3
Incorrect sample collection (unspecified) 6 2.0
Sample not in correct tube type 5 1.7
No or incorrect patient identification/label on
sample
222 21.1
Problem during sample transport 97 9.2
Delayed arrival of sample 44 45.4
Sample not frozen/on ice 24 24.7
Incorrect sample transport (unspecified) 16 16.5
Sample leakage/damage 13 13.4
Sample fixation/matrix suboptimal or
incorrect (fresh versus FFPE)
61 5.8
Samples switched 18 1.7
Mismatch between request forms and received
material
352 8.1
The number of received samples is more/
fewer than those described on the request
form
251 71.3
A request form was received without a
sample
58 16.5
The sample label does not correspond to the
identification on the form
20 5.7





Incidents (N ¼ 4363) n %
The sample localization on the form does not
match the material received
11 3.1
Processing of request form and order entry 161 3.7
Inappropriate test requested/forwarding to
incorrect department/delayed processing of
urgent sample
34 21.1
Incorrect or no patient name entered 31 19.3
Requesting service info not added or
incorrect
28 17.4
Sample labeled incorrectly 20 12.4
Incorrect date of birth entered 11 6.8
Incorrect patient identification (file number,
national registry number)
11 6.8
Incorrect sex entered 10 6.2
Booked in under incorrect sample type 10 6.2
Other 6 3.7
Abbreviations: EDTA, ethylenediaminetetraacetic acid; FFPE, formalin-
fixed, paraffin-embedded; mCRC, metastatic colorectal cancer;
NSCLC, non-small cell lung cancer.
The pre-preanalytical phase is defined as all steps from the test request
until entering of the request in the laboratory system, collected for all
hospital services. Incidents specific for NSCLC and mCRC are
presented in Table 3. The 6 unclassified incidents during processing
of the request forms and order entry (category ‘‘other’’) consisted of an
incorrect date of reception (1), problems with the automated
infrastructure for scanning of the forms (2), a missing patient file (1),
a further unspecified cause (2).
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identical percentage (12.8%) were cases with a delayed
result who were further finalized. An update of the
documentation was the main action for 33 of 123 (26.8%)
problems in the complete TTP.
For 1365 of 5168 (26.4%) incidents, the date of first
registration and date of closure were both available. From
these dates, the turnaround time was calculated, which
ranged between 1 and 411 days. Of incidents, 1018 of 1365
(74.6%) were closed at the day of creation, and another 206
of 1365 (15.1%) were closed within the first month after
creation. The average turnaround times were the lowest for
pre-preanalytical incidents and highest for incidents affect-
ing the complete test process, which are also considered the
most severe (Supplemental Figure 1). For 532 of 5168
(10.3%) of these incidents, a deadline was included for the
corrective action, which was reached in 478 of 532 (89.8%)
incidents.
Table 3. Causes of Incidents Reported for NSCLC
and mCRC Biomarker Testing
Incident Cause (N ¼ 822) n %
Preanalytical 166 20.2
Samples switched 35 21.1
Incorrect or missing sample labels during
cutting or DNA extraction
31 18.7
Sample microtomy problems (eg, incorrect
protocol/tissue used, floaters, cut too deep,
too thick, technical issues, etc)
29 17.5
Problem during sample embedding (eg,
contamination, damage, multiple tissues in
one block, etc)
17 10.2
Lost material 16 9.6
Equipment problems (errors, defects,
dispensing of reagents, etc)
14 8.4
Accompanying H&E stain missing, bad
quality, or incorrect
9 5.4
Inadequate amount of material for cutting/
extraction
8 4.8




Failed IHC or FISH test 42 15.3
Technical/server problems with autostainer or
sequencer
44 16.0
Missing, inadequate, or expired reagents 39 14.2
Incorrect sample labelling/worksheet 28 10.2
Sample switch 17 6.2
Sample lost or not tested 16 5.8
Problem with procedure (unspecified) 11 4.0
Inadequate, failed, or lack of control tissue 21 7.6
Faint/too much background FISH/IHC signal 18 6.5
Incorrect test performed/procedure not
followed
11 4.0
Insufficient/inadequate material to perform
the test
9 3.3
Failed or incorrect sequencing run 7 2.5
Sample contamination 7 2.5
Other 5 1.8
Postanalytical 194 23.6
Report content 152 78.4
Incorrect result/conclusion on report 44 28.9
Patient information (name or date of birth)
incorrect
27 17.8
Incorrect validation (too soon or too late)
of report
18 11.8
Incorrect sample localization 15 9.9
Error in microscopy part (unspecified) 13 8.6
Incorrect or absent sample number on
report, but correct result
13 8.6
Incorrect clinical history 7 4.6
Missing result on report 6 3.9
Incorrect report template used 3 2.0
Incorrect requesting physician mentioned 3 2.0
Incorrect author of report 3 2.0
Reports/results from patients switched 16 8.2
Software problem with automated result 13 6.7
No report present 6 3.1
Unexplained molecular result obtained 5 2.6
Documented procedure on reporting lacking 2 1.0
Table 3. Continued
Incident Cause (N ¼ 822) n %
Post-postanalytical 47 5.7
Results of external quality assessment
programs
26 55.3
Delayed turnaround time 16 34.0
Discrepant result reported by physician 4 8.5
Sample archiving 1 2.1
Complete TTP 123 15.0
Missing documentation or procedure 39 31.7
Maintenance/calibration not performed or too
late
20 16.3






Systematic review of CAPAs or quality
indicators
8 6.5
Document changes/versions 8 6.5
Reagents/samples storage and handling 6 4.9
Validation procedures 6 4.9
Infrastructure/equipment 5 4.1
Access to laboratory information system 5 4.1
Costs and suppliers 3 2.4
Unknown 17 2.1
Abbreviations: CAPA, corrective/preventive action; FISH, fluorescence
in-situ hybridization; H&E, hematoxylin and eosin; IHC, immunohis-
tochemistry; mCRC, metastatic colorectal cancer; NSCLS, non-small
cell lung cancer; TTP, total test process.
Phases are defined as follows: preanalytical phase, sample preparation
to perform the test (embedding, sectioning, labelling, pathology review
and/or DNA/RNA extraction); analytical phase, set-up of the analysis
sheets and the actual biomarker test and results output; postanalytical
phase, results interpretation and review until creation of the report;
post-postanalytical phase; everything after release of the results,
including participation to external quality control. Incidents in the
complete process were general system or management requirements
not related to any of the specific phases.
Incidents, such as sample switches or lost samples, could occur
throughout the test process; hence, they are shown in the phase based
on the time point of detection. Incidents are specific for NSCLC and
mCRC, in contrast to incidents covering all hospital services reported in
Table 2. The 5 unclassified incidents (category ‘‘other’’) in the analytical
phase consisted of a delayed transfer between services (2), referral of
analytical test to an external laboratory (1), limited working space for
analysis (1), and a staff member being injured (1).
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For 182 of 5168 incidents (3.5%), further follow-up was
provided, for 113 of 182 incidents in the format of a specific
preventive action, whereas for 91 of 182 incidents the
effectiveness of the performed CAPA was verified (Supple-
mental Table 3).
Four of 8 institutes also performed a risk analysis on (a
subset of) the documented incidents (n ¼ 283) (Supple-
mental Table 1). Of these 4 institutes, 2 recorded the
possible harm for patients in a descriptive manner (ie, by a
sentence stating the possible risk), while the other 2 used a
risk scale on a total of 3 or 20 points. Of the 283 incidents for
which a risk analysis was available, 209 (73.9%) yielded no
possible risk, 65 (22.9%) carried a limited-to-moderate risk,
and 9 (3.2%) conferred a possible risk to the patient
(Supplemental Table 3).
For 149 of 5168 (2.9%) entries, the channel through which
the incident was initially detected was documented or could
be deduced from the detailed description (Supplemental
Table 3). Of those 149 incidents 84 (56.4%) were first
identified during an audit, of which 6 (4.0%) by an external
audit, 33 (22.2%) by an internal audit, and for 45 (30.2%) the
audit type was unspecified. Another 26 of 149 (17.5%)
incidents were discovered by participation to EQA pro-
grams, and 15 (10.1%) during management review. Twelve
(8.1%) incidents were discovered during monitoring of the
laboratory environment, evaluation of quality indicators, or
an automatic incident system report. The remaining 9
(6.0%) and 3 (2.0%) incidents were staff suggestions and
clinician’s feedback/complaints, respectively.
The responsible staff members are shown in Figure 3, for
incident registration (A) and follow-up (B). Information
about the person who documented the incident was
available for 1368 incidents (Figure 3, A), and for 1624
incidents the person responsible for follow-up was indicated
(Figure 3, B). Of the 1368 incidents, 905 (66.2%) were
reported by an administrative officer, in 784 of 905 (86.6%)
of times due to the registration of pre-preanalytical incidents
during sample reception. Only 8 (0.6%) incidents were
reported by the laboratory director (Figure 3, A). Follow-up
of the performed actions was carried out in 1279 of 1624
(78.8%) cases by the administrative officer also (Figure 3, B).
While the molecular biologist and other staff members
(geneticists, nurses, or the requesting physicians) were
involved in 52 of 1368 (3.8%) and 9 of 1368 (0.7%) of
registered incidents, respectively (Figure 3, A), they were not
Figure 2. Relation between incidents and
corresponding ISO 15189:2012 clause. Only
incidents specific for NSCLC and mCRC were
shown. Of pre-preanalytical incidents from all
hospital services, 4363 were excluded, as
they were all related to clause 5.4: pre-
examination processes. From the remaining
822 incidents, 17 were excluded as the exact
cause was unknown and could not be linked
to the ISO standard.18 Abbreviations: ISO,
International Organization for Standardiza-
tion; mCRC, metastatic colorectal cancer;
NSCLC, non-small cell lung cancer.
Figure 3. Staff members involved in incident reporting (A) and follow-up (B).
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involved in further follow-up of the CAPAs to be
undertaken (Figure 3, B).
DISCUSSION
Accurate predictive test results are indispensable for
patient management. Laboratories are recommended to
document errors and implement the necessary CAPAs to
further improve their quality and eliminate recurring
incidents.19,20 The ISO 15189 standard requires documenta-
tion and review of incidents at regular intervals and
participation in EQA programs to verify the laboratory’s
performance.18 Even though previous studies in other fields
reported on error management, there was a need to evaluate
incidents in molecular oncology within the framework of
the TTP.
Our analysis in 8 institutes performing routine diagnostic
tests reveals that there is a wide variety in the number and
extent of incidents recorded in the LIS. As the ISO 15189
standard requires that laboratories must have a documented
procedure to identify and manage nonconformities in any
aspect of the TTP,18 there is a certain degree of freedom for
laboratories to implement this according to their needs and
within a specific software for further monitoring. In our
study, 2 nonaccredited laboratories documented fewer
incidents and less detailed information per incident (Sup-
plemental Table 1); however, the number of incidents
reported was highly variable within accredited institutes as
well. An additional evaluation with a larger number of
accredited versus nonaccredited institutes could be benefi-
cial to evaluate practices of incident reporting related to
accreditation status. Even though no evidence was provided
for better incident management by accredited laboratories in
this study because of the small number of nonaccredited
institutes, the ISO 15189 standard provides a valuable
framework for incident management. As such, laboratory
accreditation according to this ISO standard is mandatory in
some countries to perform these tests or receive test
reimbursement.
For instance, laboratories in the United States are required
to participate in accreditation programs by the College of
American Pathologists to adhere to the Clinical Laboratory
Improvement Amendments.21 In this study, the institutes
from Belgium, France, and the United Kingdom were
accredited.
Many incidents in the accredited institutes were merely a
notification of the incident without the necessity of
performing a corrective action (as exemplified by the
absence of immediate actions in Supplemental Table 2),
but were analyzed internally as quality indicators.
Looking at all hospital services, we observed a large
number of incidents still related to sample acceptance
criteria and the accompanying request forms. This was
found even in spite of template request forms and adequate
instructions for sample collection and transport for the
requesting services, which were available on the institutes’
websites. This could be explained as the pre-preanalytical
phase includes different stakeholders, which makes this
phase more difficult to monitor,22 such as the clinician,
nurses, and others involved in patient identification, data
entry, specimen collection, and transport. Also, more pre-
preanalytical incidents were documented compared with
previously reported studies with an error rate between 5%
and 12%.12 While those studies focused on this earliest
phase as part of the TTP and for only 1 hospital service, pre-
preanalytical incidents were analyzed separately in this
study because they were collected at all hospital services
(and not only for molecular pathology in NSCLC and
mCRC). This separate analysis also explains the variation in
pre-preanalytical incidents between institutes, as not all
institutes offer the same diagnostic tests, even though their
testing volume for NSCLC or mCRC biomarkers was
comparable (Supplemental Table 1). In addition, the
complexity of molecular analyses with several sample types,
biomarkers, technique types, and assays makes the pre-
preanalytical phase error prone. From the patient’s view-
point, the integrity of the entire process is important and
errors in the earliest phases should be intercepted early on.
As such, correct clinical context or patient identification are
both necessary to appropriately report the findings and
prevent sample switches. On the request form, at least a
clear description of the clinical problem to be solved by
molecular pathology should be adequately described. Also,
sample acceptance criteria should be implemented in a
laboratory. This allows a test to be performed under optimal
conditions for its validated intended use, to avoid incorrect
results in the further TTP.
Moreover, problems during test requesting and sample
collection require extra measures (such as contacting the
requesting physician or requesting a new sample) that could
impose additional patient discomfort and delayed test
results. Our findings are thus in line with previous studies,
with high error rates at the pre-preanalytical stage, with
incomplete request form filling and sample acceptance
criteria as the most frequent causes.4,5,13 Only 18.1% of
previously reported total errors were internal to the
laboratory, emphasizing the role of external causes
particularly in the pre-preanalytical and post-postanalytical
phases.4 This is exemplified in our study where only 161 of
4363 (3.7%) of all pre-preanalytical incidents were due to
incorrect entry of the received request in the system within
the laboratory itself. Other studies highlighted incorrect
sample collection as one of the main incidents, especially
for blood sample tubes.5,13 In this study, 242 of 1054
(22.9%) pre-preanalytical sample issues concerned an
incorrect blood collection (4.7% of all analyzed incidents).
While these incidents were collected for all hospital
services (and thus not specific for NSCLC or mCRC), this
is an important factor to consider for predictive biomarker
testing. Namely, many institutes have started routine
testing on liquid biopsies for the epidermal growth factor
receptor (NM_005228.5) c.2369C.T p.(Thr790Met) variant
in NSCLC, and standardization of the preanalytical
conditions in this field is currently still a main concern.23
Besides the pre-preanalytical incidents, collection of the
incidents in the subsequent phases revealed that the
analytical phase was most error prone, followed by the
postanalytical and preanalytical phases. While each phase
presented its own specific problems, one major source of
error in the postanalytical phase was the occurrence of
incorrect report content (152 of 194 [78.4%]). Although a
reduction in the analytical error rate was previously reported
due to improvements in the reliability and standardization
of analytical techniques,10 we observed a higher incident
rate at this phase compared with the preanalytical or
postanalytical phases.
Many of these analytical problems were related to failed
runs or unexpected software errors of the equipment for
which the manufacturer was contacted. Indeed, the in-
creased use of preprogrammed commercial test methods or
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automatization might lead to a black box for which
problems cannot easily be resolved by the laboratory staff.
This is in contrast to previous findings, where causes for
deviating EQA results in the analytical phase were mainly
due to inadequate test sensitivity or variant coverage, or
incorrect test interpretation, such as sequencing curves.29 It
is therefore highly recommended that laboratories partici-
pate to QA schemes, to confirm the quality of testing, data
mining, and reporting the results. As EQA participation
allows comparison to international peers, incorrect results
can be identified that might not have been detected during
routine incident reporting if technical problems are absent.
Adding to the complex test methodology is the wide
range of specimen types examined in molecular diagnostic
testing compared to other fields, such as fresh or formalin-
fixed, paraffin-embedded tissue, blood, or cytologic prepa-
rations. Every specimen type requires correct test selection,
creation of different workflows, specimen handling, and
data management.24 Moreover, there is a wide variety of
predictive markers and recommended technique types, such
as fluorescence in situ hybridization, immunohistochemis-
try, or (variant analysis by) massive parallel next-generation
sequencing panels, or commercial test methods. This variety
poses an additional challenge for reporting a correct and
complete clinical history and request, but also for reporting
multiple test results. In our study, the final report content
was indeed highly error prone. Correct reporting in a clear
and transparent format is important for the clinician to
interpret the obtained results related to the patient context,
sample limitations, and applied test methods. While several
guidelines on reporting exist,25 there is still debate on the
necessary elements to be included according to the different
intralaboratory and extralaboratory stakeholders.
Looking at the exact time point of incident detection
(Figure 1), 1%, 5%, and 1% of incidents occurred when
forwarding the sample to another service or department for
further processing of the sample or for writing the report.
This stresses the importance of identifying frequencies
and causes in the different phases, but also for continuous
quality improvement throughout the TTP. With the increas-
ing availability of next-generation sequencing to analyze
multiple biomarkers in parallel, laboratory outsourcing is
expected to increase, and hence designated professionals
with experience in multiparallel data analysis will need to be
involved. In this case, it remains the laboratory’s own
responsibility to ensure the quality of the final results.
Previous studies demonstrated that laboratories who out-
sourced a part of the analysis were indeed more likely to
have a lower performance in EQA schemes.29 The impact of
the laboratory framework and multiple transfer steps of an
individual sample on laboratory quality should be looked
into.
A small percentage (47 of 822 [5.7%]) of incidents were
reported in the post-postanalytical phase, the majority
concerning the results or availability of EQA programs, as
well as delayed results in a routine setting. Only 4 of 47
(8.5%) incidents were detected based on feedback by the
treating physician. A previous study on the follow-up of
deviating EQA results already revealed that errors in later
TTP phases are less likely to be noticed in advance by any of
the quality checks implemented at regular time points in the
TTP.29
Such incidents reported by the physician are important as
they represent errors that were not noticed before releasing
the results and could therefore harm patient safety.
Previously, the potential or actual harm of incidents on
the patient population was estimated to range from 18% to
65%, depending on the field of interest.4,9,13,26–28 In this
study, a risk analysis was documented for only a small
fraction of incidents. Of those 283 incidents, 9 (3.2%)
included a possible or actual risk to the patient. It must be
noted that we only evaluated documented incidents from
the LIS, which were corrected before releasing the results or
upon the clinician’s feedback. When re-evaluating the
documented incidents in the future, more post-postanalyt-
ical incidents might be observed in these institutes, owing to
incidents that were not yet detected, but for which feedback
might still be pending.
For instance, the requesting physician might contact the
laboratory if the patient does not respond to the therapy as
expected by the reported test outcome, which takes some
time to be noticed. Unexpected patient response to
treatment could be related to the intrinsic property of the
patient’s clinical context, but also to an incorrect test result.
These incidents might be revealed sooner with the
upcoming implementation of molecular tumor boards,
during which patient’s results are discussed together with
the laboratory and treating physician. Deviating results
might then be added directly to the patient’s clinical record
without the additional registration of the incident in the
laboratory. On the other hand, with the large frequency of
incidents being reported in the preceding phases, it might
be that test results are in fact highly accurate and the
recorded post-postanalytical incidents are actually scarce in
routine practice. Incidents in the post-postanalytical phase
and incidents affecting the complete process were less easily
resolved, as they were often more fundamental and related
to the lack of documented procedures. Also, the exact time
point of these incidents requires an investigation, which
may take additional time.
As a result of the incident, laboratories are required to
define the immediate CAPAs.18 Even though for 3953 of
5168 (76.5%) incidents no immediate actions were men-
tioned, recording of the incident for further evaluation of the
quality policy at regular intervals is good practice in this
case. For the other incidents, logical CAPAs were performed
which most often included (1) to contact requesting
physician in the pre-preanalytical phase, (2) retesting the
sample for incidents in the preanalytical or analytical phase,
(3) correcting the reports in the postanalytical phase, and (4)
communication to staff members and updating the docu-
mentation for post-postanalytical and complete TTP inci-
dents. Similar to the EQA scheme,30 appropriate CAPAs
were not limited to accredited institutes or those testing a
larger number of samples annually for common biomarkers
in NSCLC and mCRC.
Even though the institutes reported that the molecular
biologist is actively involved in follow-up of the deviating
EQA results,30 none of the CAPAs were undertaken by the
molecular biologist in this study. Also, it is not surprising
that the laboratory director was only involved in a small
percentage of incidents (Figure 3), as they are often reported
by the staff member encountering them in the laboratory.
However, the absence of these staff members in recording
the CAPAs in the system does not exclude their involve-
ment, as many incidents were discussed further via
laboratory meetings or incidents reports (Supplemental
Table 2).
To conclude, to our knowledge, for the first time in
molecular oncology, this study analyzed incidents that are
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useful for quality improvement, benchmarking, and con-
tributing to an open attitude about incident reporting with
the ultimate goal of improving patient safety. They highlight
the importance of additional quality assurance when
drafting the request forms and final reports, as well as of
participation to EQA to reflect the variety in reporting in the
individual countries.
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laire, Service de Génétique, France), Helen Stokes and Phillipe
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